Table 1.

Comparison of baseline characteristics between non-tocilizumab treated and tocilizumab-treated patients.

	Discharged ICU Patient Population (N = 96*) Data through 5/18/2020
	Non-TOCI	TOCI	P-value
	(N = 41)	(N = 55)
Outcomes
Invasive ventilation	15(36.6)	44 (80.0)	<0.001
Death	15 (36.6)	8 (14.5)	0.02
Overall Vent-free days	4.33 (±3.735)	9.68 (7.136)	0.008
Demographics
Gender
Female	21 (51.2)	11 (20.0)	0.002
Male	20 (48.8)	44 (80.0)
Age	66.59 (±19.10)	63.22 (±16.29)	0.36
Race
White	20 (48.8)	21 (38.2)	0.31
Asian	4 (9.8)	2 (3.6)
Black or African American	8 (19.5)	12 (21.8)
Hispanic	8 (19.5)	14 (25.5)
Other/Unknown	1 (2.4)	6(10.9)
Comorbidities
Hypertension	29 (70.7)	33 (60.0)	0.29
Cardiac Arrhythmias	16 (39.0)	17 (30.9)	0.52
CHF	12 (29.3)	8 (14.5)	0.13
Renal Failure	11 (26.8)	15 (27.3)	1.00
Obesity (BMI > 30)	11 (26.8)	27 (49.1)	0.04
Diabetes	20 (48.8)	27 (49.1)	1.00
Initial Lab Values
ALT	29 (10−160)	37 (10−3460)	0.07
AST	41 (16−291)	55 (16−8000)	0.27
CRP	122.3 (2.40−327.20)	122.5 (11.10−343.10)	0.94
D-DIMER	2.28 (.42−14.28)	1.12 (.37−20.00)	0.11
IL-6	42.70 (3.20−1682.80)	28.5 (3.60−6604.50)	0.98
LDH	444 (160−1193)	497.5 (210−3325)	0.01
Lymphocytes	0.875 (.06−2.89)	.44 (.00−1.63)	0.16
Neutrophils	7.12 (2.14−20.51)	5.84 (2.56–22.72)	0.50
Troponin	0.02 (.01−36.69)	0.02 (.01−25.33)	0.97
WBC	8.560 (3.27−25.96)	7.45 (3.34−26.42)	0.47
SOFA Score	5 (0−13)	4 (0−13)	0.66
Hospital days prior to tocilizumab treatment, median (range)	NA	2 (0−16)	NA
Concomitant Medications
Hydroxychloroquine	20 (48.8)	43 (78.2)	0.004
Azithromycin	22 (53.7)	47 (85.5)	0.001
Remdesivir	1 (2.4)	8 (14.5)	0.07
Dexamethasone	1 (2.4)	1 (1.8)	1.00

Data are n (%), mean (±SD), and median (range). P-values were calculated using Mann–Whitney U test, t-test, chi–square test or Fisher’s exact test, as appropriate.